Condition

Unresectable Solid Tumor

ClinicalTrials.gov condition label

Clinical trials7

Recruiting5

Common interventions17

Lead sponsors shown6

Clinical trials

7 shown

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsNCT07524322 · 2026-06-01

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationNCT06778863 · 2025-02-28

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsNCT06244771 · 2024-02-12

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08

A Beta-only IL-2 ImmunoTherapY StudyNCT05086692 · 2021-08-27

A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723 · 2026-09-01

NOT_YET_RECRUITING

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsNCT05759949 · 2023-03-29

Common interventions

FulvestrantDRUG2 AbemaciclibDRUG1 CLSP-1025DRUG1 FMC-376DRUG1 IOV-5001BIOLOGICAL1 MDNA11DRUG1 PalbociclibDRUG1 Palbociclib 125mgDRUG1 Pembrolizumab (KEYTRUDA®)DRUG1 PF-07220060 100mgDRUG1 PF-07220060 300 mgDRUG1 RGT-490DRUG1 RibociclibDRUG1 Ribociclib 400mgDRUG1 Ribociclib 600mgDRUG1 RLY-2608DRUG1 RLY-5836DRUG1

Leading sponsors

Relay Therapeutics, Inc.2 Clasp Therapeutics, Inc.1 Frontier Medicines Corporation1 Iovance Biotherapeutics, Inc.1 Medicenna Therapeutics, Inc.1 Regor Pharmaceuticals Inc.1

Trial status mix

RECRUITING5

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE17

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.